Keros Therapeutics Appoints Experienced Biopharma Executive Anne Prener to Board
KROS is trading near its 52-week low of $9.69 (7.4% above the low).
Summary
Keros Therapeutics appointed Dr. Anne Prener, a biopharma veteran with significant clinical development and executive experience, to its Board of Directors, effective July 1, 2026.
Key Events · Executive and Board Changes · KROS
-
New Director Appointed
Anne Prener, M.D., Ph.D., was appointed as a Class III director, effective July 1, 2026, with a term expiring at the 2029 annual meeting of stockholders.
-
Extensive Biopharma Experience
Dr. Prener brings significant clinical development expertise and executive leadership from previous roles as CEO of Imbria Pharmaceuticals, Freeline Therapeutics, and Gyroscope Therapeutics, as well as leadership positions at Baxalta and Novo Nordisk.
-
Standard Director Compensation
Dr. Prener will receive an initial stock option grant and restricted stock unit award each valued at $150,000, along with an annual cash retainer of $41,500 and annual equity grants valued at $150,000.
Analysis · KROS · Life Sciences
Keros Therapeutics has strengthened its board with the appointment of Dr. Anne Prener, a seasoned biopharmaceutical executive with extensive experience in clinical development and executive leadership. Her expertise is particularly valuable for a clinical-stage company like Keros as it advances its pipeline and executes its corporate strategy.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 29.2% of the 1541 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KROS was trading at $10.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $206M. The 52-week trading range was $9.69 to $22.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.